Glaxo Says Phase Three Study Of Trelegy Ellipta Meets Primary Endpoint
LONDON (Alliance News) - GlaxoSmithKline PLC and its partner Innoviva Inc on Thursday said the phase three Captain study of once-daily single inhaler triple therapy Trelegy Ellipta met its primary Read More